Current Status of the Pharmacological Treatment of Glaucoma and Its Prospects
Glaucoma, the leading cause of blindness in adults, is a progressive neurodegenerative disease characterized by retinal ganglion cell (RGC) death. Currently, many intraocular pressure (IOP)-lowering drugs known to affect this disease progression have been developed as therapeutic agents. However, there are many cases of disease progression, even with sufficient IOP reduction. Therefore, newer therapeutic approaches other than IOP-lowering drugs are needed. To elucidate the pathogenesis of glaucoma and to develop therapeutic agents, the evaluation of RGCs is imperative, as their degeneration is the main cause of this disease. However, it is difficult to obtain RGCs from healthy individuals, let alone glaucoma patients. Therefore, research on the pathophysiology of glaucoma and drug discovery has not progressed sufficiently. Recent developments have made it possible to generate induced pluripotent stem (iPS) cells from the blood or skin of glaucoma patients and induce them to differentiate into RGCs to study the pathogenesis of glaucoma. In addition, drug repositioning for ophthalmological diseases such as glaucoma is one of the most active fields. Many of these repositioned drugs have found therapeutic applications in ophthalmology. Here, we introduce the current status of the pharmacological treatment of glaucoma and its prospects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 141(2021), 1 vom: 21., Seite 61-66 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Shimazawa, Masamitsu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug repositioning |
|---|
| Anmerkungen: |
Date Completed 15.02.2021 Date Revised 15.02.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1248/yakushi.20-00177-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319544508 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319544508 | ||
| 003 | DE-627 | ||
| 005 | 20231225171659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.1248/yakushi.20-00177-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319544508 | ||
| 035 | |a (NLM)33390449 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Shimazawa, Masamitsu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Status of the Pharmacological Treatment of Glaucoma and Its Prospects |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2021 | ||
| 500 | |a Date Revised 15.02.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Glaucoma, the leading cause of blindness in adults, is a progressive neurodegenerative disease characterized by retinal ganglion cell (RGC) death. Currently, many intraocular pressure (IOP)-lowering drugs known to affect this disease progression have been developed as therapeutic agents. However, there are many cases of disease progression, even with sufficient IOP reduction. Therefore, newer therapeutic approaches other than IOP-lowering drugs are needed. To elucidate the pathogenesis of glaucoma and to develop therapeutic agents, the evaluation of RGCs is imperative, as their degeneration is the main cause of this disease. However, it is difficult to obtain RGCs from healthy individuals, let alone glaucoma patients. Therefore, research on the pathophysiology of glaucoma and drug discovery has not progressed sufficiently. Recent developments have made it possible to generate induced pluripotent stem (iPS) cells from the blood or skin of glaucoma patients and induce them to differentiate into RGCs to study the pathogenesis of glaucoma. In addition, drug repositioning for ophthalmological diseases such as glaucoma is one of the most active fields. Many of these repositioned drugs have found therapeutic applications in ophthalmology. Here, we introduce the current status of the pharmacological treatment of glaucoma and its prospects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a drug repositioning | |
| 650 | 4 | |a glaucoma | |
| 650 | 4 | |a intraocular pressure | |
| 650 | 4 | |a retinal ganglion cell | |
| 700 | 1 | |a Hara, Hideaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan |d 1961 |g 141(2021), 1 vom: 21., Seite 61-66 |w (DE-627)NLM000042153 |x 1347-5231 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2021 |g number:1 |g day:21 |g pages:61-66 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1248/yakushi.20-00177-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2021 |e 1 |b 21 |h 61-66 | ||